YC W22
Alixia
Targeting the Tumor Ecosystem to address cancer drug resistance.
About
Our compounds disrupt the metabolic and inflammatory triggers in both cancer and quasi-cancerous cells in the tumor microenvironment. By impacting multiple cell types, we are enabling effective, lasting cancer treatments.
Founders
- Olof Mollstedt
- Helen Chen
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Alixia.
See family office activityIndustry & Focus
HealthcareTherapeuticsBiotechDrug discoveryOncologyBiotechnology